• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $79 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-50 Mln

Hookipa Pharma Inc (HOOK) Share Price

$0.77

As on 01-Mar-2024 16:04 EST

up-down-arrow $0.000.27%

  • Prev Close info

    $0.77

  • Day's Openinfo

    $0.79

  • Today's Highinfo

    $0.80

  • Today's Lowinfo

    $0.75

  • Today's Volumeinfo

    299,140

  • 52 Week rangeinfo

    $0.41 - 2.05

Please wait...

Hookipa Pharma Inc (HOOK) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Hookipa Pharma Inc (HOOK)
-4.93 23.99 35.34 -10.97 -59.78 -- --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
Hookipa Pharma Inc (HOOK)
0.00 -65.24 -78.99 -9.32
S&P Small-Cap 600
13.89 -17.42 25.27 9.57
S&P BSE Sensex
18.74 4.44 21.99 15.75

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Hookipa Pharma Inc (HOOK) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Hookipa Pharma Inc (HOOK)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Hookipa Pharma Inc (HOOK)

        CEO & Director

        Mr. Joern Aldag

        CFO & Director

        Dr. Reinhard Kandera Ph.D.

        Headquarters

        New York, NY

        FAQs for Hookipa Pharma Inc (HOOK)

        The total asset value of Hookipa Pharma Inc (HOOK) stood at $ 205 Mln as on 30-Sep-23

        The share price of Hookipa Pharma Inc (HOOK) is $0.77 (NASDAQ) as of 01-Mar-2024 16:04 EST. Hookipa Pharma Inc (HOOK) has given a return of -59.78% in the last 3 years.

        Hookipa Pharma Inc (HOOK) has a market capitalisation of $ 79 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Hookipa Pharma Inc (HOOK) is 0.82 times as on 29-Feb-2024, a -0.72% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Hookipa Pharma Inc (HOOK) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Hookipa Pharma Inc (HOOK) and enter the required number of quantities and click on buy to purchase the shares of Hookipa Pharma Inc (HOOK).

        HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York. Address: 350 Fifth Avenue, New York, NY, United States, 10118

        The CEO & director of Mr. Joern Aldag. is Hookipa Pharma Inc (HOOK), and CFO & Sr. VP is Dr. Reinhard Kandera Ph.D..

        The promoters of Hookipa Pharma Inc (HOOK) have pledged 0% of the total equity as on Sep-23.

        Hookipa Pharma Inc (HOOK) Ratios
        Return on equity(%)
        -77.87
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Hookipa Pharma Inc (HOOK) was $-50 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $79.16 Mln
        • Revenue (TTM)revenue-information $20.55 Mln
        • Earnings (TTM) earning-information $-50.01 Mln
        • Cash date-information $107.68 Mln
        • Total Debt info $3.85 Mln
        • Insider's Holding 23.19%
        • Liquidity liquidity High
        • 52 Week range week-range $0.41 - 2.05
        • Shares outstanding share-outstanding 96,550,600
        • 7 Years Aggregate:

          CFO: $-227.16 Mln

          EBITDA: $-271.87 Mln

          Net Profit: $-306.79 Mln

        About The Company

        • IPO Date 18-Apr-2019
        • CEO & Director Mr. Joern Aldag
        • CFO & Director Dr. Reinhard Kandera Ph.D.
        • Listing key-listing NASDAQ: HOOK
        • Country United States
        • Headquarters headquarters New York, NY
        • Website website https://www.hookipapharma.com
        • Business

          HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101,...  which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York. Address: 350 Fifth Avenue, New York, NY, United States, 10118  Read more

        share-fund-plan-icon